Remove 2017 Remove 2023 Remove Informed consent
article thumbnail

Analysis of U.S. Food and Drug Administration Draft Guidance on Clinical Trials with Psychedelic Drugs

Healthcare Law Insights blog

On June 23, 2023 the U.S. FDA recommends referring to its 2017 guidance “Assessment of Abuse Potential of Drugs” for details. All comments should be identified with the docket number FDA-2023-D-1987. FDA also recommends characterizing the dose-response relationship, as this is poorly understood for most psychedelic drugs.

article thumbnail

Caring for the Unrepresented: A Podcast with Joe Dixon, Timothy Farrell, Yael Zweig

GeriPal

Tim 07:37 I was going to say the terminology really came from the legal literature that we kind of adopted, I think in that 2017 statement. But I remember very clearly, not too long after the 2017 statement was published, our office administrative assistant said, hey Tim, you got a phone call from someone I didn’t recognized.

article thumbnail

5 Risk Control Considerations as Nurse Practitioners’ Scope of Practice Expands

Minority Nurse

Since 2023, 27 states and the District of Columbia have granted NPs full practice authority (AANP, 2023). Where NPs have reduced or restricted practice authority to provide patient care, liability is often shared with supervising physicians (Candello, 2023). of claims in 2017 to 37.1% Informed Consent.